In children, lesions caused by the human papillomavirus (HPV) constitute a significant epidemiological issue and a therapeutic dilemma, particularly in the case of anogenital warts. The treatment of anogenital warts in children is a challenge, since standard treatments are generally painful and require the patient to be anesthetized. Imiquimod, a topical immune response modifier, constitutes an alternative therapeutic agent for the treatment of HPV. The present report describes four cases in which treatment with topically applied imiquimod 5% cream was implemented with successful results.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1590/s0365-05962010000400020 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Augmented immunogenicity of the HPV16 DNA vaccine via dual adjuvant approach: integration of CpG ODN into plasmid backbone and co-administration with IL-28B gene adjuvant.
Virol J
January 2025
Institute of Basic Medical Sciences Chinese Academy of Medical Sciences, School of Basic Medicine Peking Union Medical College, Beijing, China.
Therapeutic human papillomavirus (HPV) DNA vaccine is an attractive option to control existed HPV infection and related lesions. The two early viral oncoproteins, E6 and E7, are continuously expressed in most HPV-related pre- and cancerous cells, and are ideal targets for therapeutic vaccines. We have previously developed an HPV 16 DNA vaccine encoding a modified E7/HSP70 (mE7/HSP70) fusion protein, which demonstrated significant antitumor effects in murine models.
View Article and Find Full Text PDFPilot Testing Digital Stories to Influence College Men's Intentions to Vaccinate Against HPV.
J Cancer Educ
January 2025
Edson College of Nursing and Health Innovation, Arizona State University, Phoenix, AZ, USA.
College men are among those least likely to be vaccinated against the human papillomavirus (HPV). Viewing digital stories from other college men who were vaccinated against HPV as young adults may help influence them to seek the vaccine. Guided by the Theory of Planned Behavior, this research reports on the creation and pilot testing of digital stories to increase college men's intentions to vaccinate against HPV.
View Article and Find Full Text PDFExploring intersectional determinants of, and interventions for, low uptake of human papillomavirus vaccine in sub-Saharan Africa: a scoping review protocol.
BMJ Open
January 2025
Department of Computing and Information Technology, University of Embu, Embu, Kenya.
Introduction: Cervical cancer is the most diagnosed cancer and the leading cause of cancer-related death in 36 low- and middle-income countries, with the majority located in sub-Saharan Africa (SSA), South America and Southeastern Asia. The highest regional incidence and mortality occur in SSA. Despite the high efficacy and cost-effectiveness of the human papillomavirus (HPV) vaccine in preventing cervical cancer, its uptake remains unacceptably low in SSA.
View Article and Find Full Text PDFClinical Benefit of a Conservative Treatment for High-Risk Human Papillomavirus Lesions in Patients with HIV.
AIDS Res Hum Retroviruses
January 2025
Servicio de Ginecología y Obstetricia, Hospital Universitario Torrecárdenas, GAEPI-VPH (Grupo Andaluz para el Estudio y la Prevención de la Infección por VPH), Almería, Spain.
Infection with Human immunodeficiency virus (HIV) shows a higher risk of infection by Human papillomavirus (HPV). We aim to provide evidence about the effect of a -based vaginal gel (Papilocare®) for treating HPV in women with HIV. Women ≥25 years coinfected by endocervical HPV and with low-grade abnormal cervicovaginal cytology were treated for 6 months with Papilocare® in this observational, prospective, non-controlled pilot study.
View Article and Find Full Text PDFTtrAgo-mediated nucleic acid detection system and portable device for rapid detection of sexually transmitted diseases.
Biosens Bioelectron
December 2024
Hanshan Normal University, Chaozhou, Guangdong Province, China. Electronic address:
The development of rapid and multiplexed point-of-care (POC) diagnostic tools is vital for the prevention and control of sexually transmitted diseases (STIs). Here, we developed a POC-comprehensive Thermococcus thioreducensArgonaute (TtrAgo)-mediated nucleic acid detection system (POC-CANDY) and palm-sized portable detection device "Owl-1" for the simultaneous detection of Ureaplasma urealyticum, Chlamydia trachomatis, Neisseria gonorrhoeae, human papillomavirus types 16/18 and antibiotic resistance molecular markers [tetM, and gyrA mutation (S91F)]. Using recombinase polymerase amplification (RPA), the optimized POC-CANDY could finish the whole detection procedure within 55 min and achieve a limit of detection of 10 copies/μL.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!